London-based consultancy Clark Health Communications is partnering with digital solutions agency Egg in a collaboration that will see them offer their services to each other’s clients.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.